Anti-CD38 human antibodies and uses thereof
The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These antibodies, accordingly, can be used to treat, for example, hematological malignancies such as multiple myeloma. Antibodies of the invention also can be used in the diagnostics field, as well as for investigating the role of CD38 in the progression of disorders associated with malignancies. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use. The invention also provides isolated novel epitopes of CD38 and methods of use therefore.
1. An isolated human antibody that specifically binds an epitope of CD38 (SEQ ID NO: 22),
wherein said antibody mediates killing of a CD38+ target cell by antibody dependent cellular cytotoxicity with at least five-fold better efficacy than chimeric OKT10 antibody (SEQ ID NOS: 23 and 24) under the same or substantially the same conditions when a human PBMC cell is employed as the effector cell,
wherein said CD38+ target cell is selected from the group consisting of LP-1 (DSMZ: ACC41) and RPMI-8226 (ATCC: CCL-155), and
wherein the ratio of effector cells to target cells is between about 30:1 and about 50:1.
2. An isolated antibody according to claim 1 , comprising an H-CDR1, H-CDR2 and H-CDR3 depicted in SEQ ID NO: 5 and an L-CDR1, L-CDR2 and L-CDR3 depicted in SEQ ID NO: 13.
3. An isolated antibody according to claim 1 , comprising an H-CDR1, H-CDR2 and H-CDR3 depicted in SEQ ID NO: 6 and an L-CDR1, L-CDR2 and L-CDR3 depicted in SEQ ID NO: 14.
4. An isolated antibody according to claim 1 , comprising an H-CDR1, H-CDR2 and H-CDR3 depicted in SEQ ID NO: 7 and an L-CDR1, L-CDR2 and L-CDR3 depicted in SEQ ID NO: 15.
5. An isolated antibody according to claim 1 , comprising an H-CDR1, H-CDR2 and H-CDR3 depicted in SEQ ID NO: 8 and an L-CDR1, L-CDR2 and L-CDR3 depicted in SEQ ID NO: 16.
6. An isolated antibody to according to claim 1 , which is an IgG.
7. An isolated antibody to according to claim 6 , which is an IgG1.
8. An isolated human antibody that specifically binds to an epitope of CD38 (SEQ ID NO: 22),
wherein said antibody mediates killing of a CD38-transfected CHO cell by cell dependent cytotoxicity with at least two-fold better efficacy than chimeric OKT10 antibody (SEQ ID NOS: 23 and 24) under the same or substantially the same conditions.
9. An isolated antibody according to claim 8 , comprising an H-CDR1, H-CDR2 and H-CDR3 depicted in SEQ ID NO: 5 and an L-CDR1, L-CDR2 and L-CDR3 depicted in SEQ ID NO: 13.
10. An isolated antibody according to claim 8 , comprising an H-CDR1, H-CDR2 and H-CDR3 depicted in SEQ ID NO: 6 and an L-CDR1, L-CDR2 and L-CDR3 depicted in SEQ ID NO: 14.
11. An isolated antibody according to claim 8 , comprising an H-CDR1, H-CDR2 and H-CDR3 depicted in SEQ ID NO: 7 and an L-CDR1, L-CDR2 and L-CDR3 depicted in SEQ ID NO: 15.
12. An isolated antibody to according to claim 8 , which is an IgG.
13. An isolated antibody to according to claim 12 , which is an IgG1.
14. An isolated human or humanized antibody or antibody fragment thereof containing an antigen-binding region which specifically binds within amino acids 44 to 206 of CD38 (SEQ ID NO: 22).
15. An isolated antibody or antibody fragment thereof containing an antigen-binding region of claim 14 , which specifically binds within amino acids 44-66, 82-94, 142-154, 148-164, 158-170, or 192-206 of CD38 (SEQ ID NO: 22).
16. An isolated antibody or antibody fragment thereof containing an antigen-binding region of claim 15 , which specifically binds within amino acids 44-66 or 148-164 of CD38 (SEQ ID NO: 22).
17. An isolated antibody or antibody fragment thereof containing an antigen-binding region of claim 16 , which specifically binds within amino acids 44-66 and 148-164 of CD38 (SEQ ID NO: 22).
18. An isolated antibody or antibody fragment thereof containing an antigen-binding region of claim 15 , which specifically binds within amino acids 192-206 of CD38 (SEQ ID NO: 22).
19. An isolated antibody or antibody fragment thereof containing an antigen-binding region of claim 15 , which specifically binds within amino acids 82-94 or 158-170 of CD38 (SEQ ID NO: 22).
20. An isolated antibody or antibody fragment thereof containing an antigen-binding region of claim 19 , which specifically binds within amino acids 82-94 and 158-170 of CD38 (SEQ ID NO: 22).
21. An isolated antibody or antibody fragment thereof containing an antigen-binding region of claim 15 , which specifically binds within amino acids 82-94 or 142-154 of CD38 (SEQ ID NO: 22).
22. An isolated antibody or antibody fragment thereof containing an antigen-binding region of claim 21 , which specifically binds within amino acids 82-94 and 142-154 of CD38 (SEQ ID NO: 22).
23. An isolated antibody or antibody fragment thereof containing an antigen-binding region according to claim 14 , comprising an H-CDR1, H-CDR2 and H-CDR3 depicted in SEQ ID NO: 5 and an L-CDR1, L-CDR2 and L-CDR3 depicted in SEQ ID NO: 13.
24. An isolated antibody or antibody fragment thereof containing an antigen-binding region according to claim 14 , comprising an H-CDR1, H-CDR2 and H-CDR3 depicted in SEQ ID NO: 6 and an L-CDR1, L-CDR2 and L-CDR3 depicted in SEQ ID NO: 14.
25. An isolated antibody or antibody fragment thereof containing an antigen-binding region according to claim 14 , comprising an H-CDR1, H-CDR2 and H-CDR3 depicted in SEQ ID NO: 7 and an L-CDR1, L-CDR2 and L-CDR3 depicted in SEQ ID NO: 15.
26. An isolated antibody or antibody fragment thereof containing an antigen-binding region according to claim 14 , comprising an H-CDR1, H-CDR2 and H-CDR3 depicted in SEQ ID NO: 8 and an L-CDR1, L-CDR2 and L-CDR3 depicted in SEQ ID NO: 16.
27. An isolated antibody according to claim 14 , which is an IgG.
28. An isolated antibody according to claim 27 , which is an IgG1.